Pharma: Clinic Roundup
Thursday, April 19, 2012
Boehringer Ingelheim GmbH, of Ingelheim, Germany, said a retrospective subanalysis of the 18,113-patient RE-LY trial showed lower rates of intracranial hemorrhage (ICH), including both fatal and traumatic ICH, for Pradaxa (dabigatran etexilate mesylate) capsules 150 mg taken twice daily, compared to warfarin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.